Clinical Trial Update: Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating donafenib combined with TACE as adjuvant therapy for hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Donafenib (donafenib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN